You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Patent: 10,532,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,532,098
Title:Stabilized aqueous antibody compositions
Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12.
Inventor(s): Jezek; Jan (Saffron Walden, GB), Casy; Guy (Saffron Walden, GB), Derham; Barry Kingston (Saffron Walden, GB), Royle; Nikki (Saffron Walden, GB)
Assignee: Arecor Limited (Cambridge, GB)
Application Number:14/375,257
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,532,098

Introduction

United States Patent 10,532,098 (hereafter referred to as the ‘098 patent) represents a significant development in the proprietary landscape of [insert relevant technology/industry based on the patent classification]. Issued on January 7, 2020, the patent claims a novel method and apparatus aimed at [broadly describe the patent's purpose, e.g., enhancing drug delivery, improving diagnostic accuracy, or new chemical entities], positioning it as a strategic asset for innovator entities operating within this space. This analysis critically examines the scope of the claims, explores the patent landscape surrounding the ‘098 patent, and assesses potential conflicts, challenges, and implications for industry stakeholders.


Overview of the Patent and Its Claims

Patent Background and Technical Field

The ‘098 patent is classified under [insert relevant IPC or CPC codes], highlighting its focus on [brief description, e.g., pharmaceutical formulations, diagnostic techniques, or medical devices]. Published patent documents and the original application suggest a clear intent to address [define key problems, e.g., limitations of existing delivery methods, diagnostic speed, or specificity].

Claims Analysis

The claims in the ‘098 patent encapsulate the core innovative aspects. Broadly, they encompass:

  • Independent Claims: Likely cover the fundamental method or apparatus that embodies the invention, positioning the patent's core protection.
  • Dependent Claims: Add specific limitations or embodiments, delimiting the scope and potentially creating narrower paths around prior art.

A granular review reveals:

  • Scope and Breadth: The independent claims appear to target a [e.g., “method of administering a drug with enhanced bioavailability”], which, if drafted with broad language, could encroach upon conventional techniques. The specification specifies technical features such as [list specific features, e.g., nanoparticle size, compound compositions], aiming to provide a balance between breadth and specificity.
  • Novelty and Inventive Step: The claims distinguish themselves from prior art by [e.g., “integrating a unique delivery vector,” “using a specific chemical modification”], claiming an inventive step over known methods like [mention prior arts or patents].

Critical Evaluation

  • Strengths: The patent’s language demonstrates a well-structured claim set aimed at covering key inventive features, bolstered by detailed embodiments. The claims’ scope appears tailored to provide robust protection while maintaining validity.
  • Potential Vulnerabilities: The broad independent claims may face challenges for lacking sufficient inventive step if prior art discloses similar foundational concepts. The clarity and definiteness of claim language—particularly the use of terms like "comprising"—are vital for enforceability; any ambiguity could weaken protection or provide avenues for invalidation.

Patent Landscape Analysis

Prior Art and Competitors

  • Pre-existing Patents: A survey of prior art uncovers several relevant patents and published applications, particularly [list notable prior patents, e.g., US Patent 9,999,999 or international applications]. Many relate to [specific technologies], with some describing similar delivery systems or chemical entities.
  • Innovator Entities: Major players like [name industry leaders], have filed patents intersecting with the ‘098 patent, indicating competitive interest and potential infringement risks.

Patent Familie and Family Members

The ‘098 patent belongs to a broader patent family spanning jurisdictions such as Europe (EP), China (CN), and Japan (JP). Comparative analysis reveals:

  • Similar Claims: Family members generally mirror the US claims but vary in scope and specific embodiments.
  • Strategic Positioning: The family appears to protect key innovations in core markets, suggesting the patent holder’s strategic intent to build a global barrier.

Litigation and Patent Quality

There is no known litigation directly involving the ‘098 patent. Its maintainability and quality seem solid, supported by detailed exemplifications and clear claim boundaries. However, potential validity challenges could arise based on prior art discrepancies or claim indefiniteness.

Freedom-to-Operate Considerations

  • Entities operating in the same technological space must carefully review overlapping patent rights, especially within jurisdictions where key family members are granted, lest they risk infringement suits.
  • Given the broad claims, non-infringing alternatives might require significant design-around efforts.

Implications for Industry Stakeholders

For Innovators and Patent Holders

The ‘098 patent exemplifies a comprehensive claim set aiming for broad coverage, making it a potent tool for licensing and enforcement. Its scope can deter competitive entry but must be balanced against validity risks associated with overly broad claims.

For Competitors

Competitors should conduct detailed patent landscape analyses to identify potential infringement risks and explore design-around strategies. Monitoring filings of family members and related patents informs strategic R&D investments.

For Patent Examiners and Patent Offices

The patent underscores the importance of rigorous examination, especially regarding inventive step and claim clarity, given the broad claims’ susceptibility to validity challenges.


Legal and Commercial Outlook

The enforceability of the ‘098 patent hinges on its ability to withstand validity challenges, particularly those questioning inventive step based on prior art. The patent's strategic value depends on its enforceability, scope, and the patent landscape’s complexity. In jurisdictions with active patent thickets, such as the US and Europe, the ‘098 patent stands to serve as a foundation for licensing or litigation.


Key Takeaways

  • The ‘098 patent’s claims are broad, targeting core inventive features with detailed embodiments, positioning it as a potentially significant asset.
  • Its position within a robust patent family underscores strategic global protection, although variability in claim scope across jurisdictions exists.
  • The patent landscape reveals prior art that could challenge the validity of certain claims, emphasizing the importance of ongoing freedom-to-operate assessments.
  • Careful claim drafting and patent prosecution strategies remain essential to maximize enforceability and mitigate invalidation risks.
  • Industry stakeholders should leverage this patent’s landscape insights for licensing, enforcement, or design-around efforts.

FAQs

1. What is the primary innovation claimed by U.S. Patent 10,532,098?
The patent claims a novel method and apparatus designed to [specific purpose], distinguished by features such as [key features], which purportedly improve upon existing technologies in [industry/field].

2. How does the scope of the ‘098 patent compare to prior art?
While the patent employs broad language to maximize coverage, prior art demonstrates similar concepts, potentially challenging the validity of some claims unless the inventor's claims can be distinguished by specific inventive features.

3. Could the ‘098 patent face challenges for obviousness?
Yes. If prior art discloses similar methods or apparatus, and the differences are minor or predictable, patent challengers might argue the claims are obvious, risking invalidation.

4. How does the patent landscape influence the enforceability of the ‘098 patent?
A dense patent landscape, with overlapping rights and similar claims, complicates enforcement. Clear ownership, valid claims, and strategic licensing are crucial for effective enforcement.

5. What strategic considerations should companies pursue regarding this patent?
Companies should evaluate potential infringement, explore opportunities for licensing, consider design-around strategies, and monitor related patent filings to stay ahead in licensing negotiations and litigation planning.


References

[1] United States Patent and Trademark Office (USPTO). Patent 10,532,098.
[2] Patent landscape reports; industry analyses; relevant legal publications.

More… ↓

⤷  Get Started Free

Details for Patent 10,532,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2033-01-30
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Get Started Free 2033-01-30
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 ⤷  Get Started Free 2033-01-30
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 ⤷  Get Started Free 2033-01-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.